News

Verona Pharma's flagship drug last year became the first new maintenance treatment for chronic obstructive pulmonary disease ...
Merck on Thursday said the application covers the investigational, once-daily, oral two-drug regimen for adults with HIV-1 infection that is virologically suppressed on antiretroviral therapy. The ...
Merck is a massive company with strong fundamentals and underlying value at a heavily discounted price. Click here to find ...
China’s first domestically made nine-valent HPV vaccine, a direct competitor to Merck’s Gardasil 9, is being priced at 499 ...
Merck is set to announce its second-quarter results later this month, and analysts anticipate double-digit earnings dip.
Merck & Co., Inc. (NYSE:MRK) is one of the 10 best defensive stocks to buy in a volatile market. On July 2, UBS reiterated a ...
Merck will buy UK-based Verona Pharma for about $10 billion, the companies said on Wednesday, strengthening the U.S. firm's ...